- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-07985045, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 227
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole
- Drug
- Lead sponsor
- Nuvalent Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 21
- States / cities
- Orange, California • Sacramento, California • Stanford, California + 16 more
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Adenocarcinoma
- Interventions
- CK-101
- Drug
- Lead sponsor
- Checkpoint Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • St Louis, Missouri • Hackensack, New Jersey + 1 more
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors
- Interventions
- CDX-527
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more
- Conditions
- Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors
- Interventions
- AMG 794
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 1 more
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
- Interventions
- TNG348, Olaparib
- Drug
- Lead sponsor
- Tango Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Orange City, Florida • Sarasota, Florida + 3 more
- Conditions
- Solid Tumor
- Interventions
- ROSE12, Atezolizumab, Pembrolizumab
- Drug
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Philadelphia, Pennsylvania • Providence, Rhode Island • Nashville, Tennessee + 2 more
- Conditions
- Cancer, Solid Tumors
- Interventions
- Vevorisertib, Fulvestrant, Paclitaxel
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Las Vegas, Nevada • Oklahoma City, Oklahoma • Charleston, South Carolina + 3 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- ERAS-601, Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Sarasota, Florida • Boston, Massachusetts + 9 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- Naporafenib, Trametinib
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- San Francisco, California • New Haven, Connecticut • Sarasota, Florida + 10 more
- Conditions
- Advanced Solid Tumor
- Interventions
- YL201, YL201 and atezolizumab
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 19
- States / cities
- Fair Oaks, California • La Jolla, California • Lone Tree, Colorado + 16 more
- Conditions
- Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
- Interventions
- larotrectinib(Vitrakvi, BAY2757556)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Not listed
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 33
- States / cities
- Los Angeles, California • Newport Beach, California • Palo Alto, California + 28 more
- Conditions
- Pancreatic Cancer
- Interventions
- Romidepsin, Gemcitabine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cancer
- Interventions
- MEDI-522
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Clear-Cell Renal Cell Carcinoma
- Interventions
- Sitravatinib, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
- Interventions
- CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy
- Drug
- Lead sponsor
- Tactical Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 4
- States / cities
- New York, New York • Portland, Oregon
- Conditions
- Sarcoma, Solid Tumor
- Interventions
- RAD001, CP-751,871
- Drug
- Lead sponsor
- Suzanne George, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- gemcitabine hydrochloride, paclitaxel
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
- Interventions
- Avapritinib, midazolam
- Drug
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Ann Arbor, Michigan • Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
- Interventions
- Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
- Conditions
- KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
- Interventions
- TPX-0005, Trametinib
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- California City, California • Denver, Colorado • Nashville, Tennessee + 2 more
- Conditions
- Advanced Pancreatic Cancer, Advanced Solid Tumor
- Interventions
- Metformin, Simvastatin, Digoxin
- Drug
- Lead sponsor
- Danae Hamouda, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib, pemetrexed disodium, gene expression analysis, mutation analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunohistochemistry staining method
- Drug · Genetic · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Solid Tumor
- Interventions
- SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 9
- States / cities
- Newark, Delaware • Iowa City, Iowa • Westwood, Kansas + 6 more